Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Asymptomatic hyperuricemia

INTRODUCTION

Asymptomatic hyperuricemia is the term applied to settings in which the serum urate concentration is elevated, but neither symptoms nor signs of urate crystal deposition (gout) have occurred. Although gout may develop in a hyperuricemic individual at any point, it is likely that two-thirds or more of hyperuricemic individuals will remain asymptomatic [1-5]. The implications of hyperuricemia may be broadly regarded as those related to urate or uric acid crystal deposition and those emerging from crystal deposition-unrelated associations of hyperuricemia with important disorders, including hypertension, chronic kidney disease, cardiovascular disease, and the insulin resistance syndrome.

The etiology and management of asymptomatic hyperuricemia will be reviewed here. Gout, uric acid renal diseases, and uric acid nephrolithiasis are discussed separately. (See "Clinical manifestations and diagnosis of gout" and "Treatment of acute gout" and "Prevention of recurrent gout" and "Uric acid renal diseases" and "Uric acid nephrolithiasis".)

DEFINITIONS

The statistical definition of hyperuricemia is difficult to accept because of non-normal distribution of serum urate concentrations in most populations. For purposes relating to urate crystal deposition, a definition of hyperuricemia based on the solubility limit of urate in body fluids (ie, the concentration at which a state of supersaturation for urate is reached in the serum) is appropriate. This physicochemical definition corresponds to urate concentrations exceeding about 7.0 mg/dL (416 mmol/L), as measured by automated enzymatic (uricase) methods in routine clinical laboratory use. These values are approximately 1 mg/dL (60 mmol/L) lower than those obtained with colorimetric methods.

A definition of hyperuricemia appropriate to the non-crystal deposition-associations of hyperuricemia with the conditions listed above is more problematic for two reasons: first, the high prevalence of urate values exceeding saturation but within 2 standard deviations of the population mean (for example, an estimated 5 to 8 percent in adult white males in the US and 25 percent in Taiwan Chinese males [6]); and second, the fact that associations of serum urate levels with cardiovascular and other disorders are manifested at concentrations that are clearly subsaturating [7].

Classification — Persistent hyperuricemia is a common biochemical abnormality that results from excessive urate production and/or diminished renal uric acid excretion [8]. (See "Uric acid balance".)

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Campion, EW, Glynn, RJ, DeLabry, LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421.
  2. Langford, HG, Blaufox, MD, Borhani, NO, et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147:645.
  3. Hall, AP, Barry, PE, Dawber, TR, McNamara, PM. Epidemiology of gout and hyperuricemia: A long term population study. Am J Med 1967; 42:27.
  4. Fessel, WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67:74.
  5. Johnson, RJ, Feig, DI, Herrera-Acosta, J, Kang, DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45:18.
  6. Lin, KC, Lin, HY, Chou, P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27:1045.
  7. Sanchez-Lozada, LG, Tapia, E, Rodriguez-Iturbe, B, et al. Hemodynamics of hyperuricemia. Semin Nephrol 2005; 25:19.
  8. Wyngaarden, JB, Kelley, WN. Gout and hyperuricemia. Grune and Stratton, New York, 1976.
  9. Anton, FM, Garcia Puig, J, Ramos, T, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 1986; 35:343.
  10. Ljubojevic, M, Herak-Kramberger, CM, Hagos, Y, et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol 2004; 287:F124.
  11. Kjellstrand, CM, Campbell, DC, von Hartitzach, B, Buselmeier, TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.
  12. Liang, MH, Fries, JF. Asymptomatic hyperuricemia. The case for conservative management. Ann Intern Med 1978; 88:666.
  13. Choi, HK, Atkinson, K, Karlson, EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277.
  14. Choi, HK, Atkinson, K, Karlson, EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093.
  15. Lin, KC, Lin, HY, Chou, P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27:1501.
  16. Choi, HK, Atkinson, K, Karlson, EW, Curhan, G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742.
  17. Yü, T-F, Gutman, AB. Uric acid nephrolithiasis in gout: Predisposing factors. Ann Intern Med 1967; 67:1133.
  18. Shadick, NA, Kim, R, Weiss, S, et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: The normative aging study. J Rheumatol 2000; 27:1708.
  19. Murray, T, Goldberg, M. Chronic interstitial nephritis: Etiologic factors. Ann Intern Med 1975; 82:453.
  20. Singer, JZ, Wallace, SL. The allopurinol hypersensitivity syndrome: Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29:82.
  21. Hande, KR, Noone, RM, Stone, WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47.
  22. Becker, MA. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 1988; 14:377.
  23. Yu, TF. Urolithiasis in hyperuricemia and gout. J Urol 1981; 126:424.
white circle LOG IN
white circle DEMO